Navigation Links
MicroMass President Jay Bigelow Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences
Date:7/31/2008

lopment among his colleagues, championing courage, honesty and integrity.

"Being named to the PharmaVOICE 100 is a big honor, and I'm humbled and thankful to everyone who thought me worthy of it and everyone whose talent, passion and achievements have made my own successes possible," Bigelow said. "There are some exceptionally visionary people working in the life sciences, and, to paraphrase Sir Isaac Newton, anytime I've been able to see farther than others, it was because I was standing on the shoulders of giants."

Visit http://www.micromass.com/news/in_the_know.jsp# to read full details on Bigelow's selection to the PharmaVOICE 100.

About MicroMass Communications, Inc.

MicroMass personalizes brands. Founded in 1994, MicroMass is a relationship marketing agency with unrivalled capabilities in the use of behavioral science for gaining and applying deep consumer insights. The company's approach is founded on MicroMass President Jay Bigelow Named to PharmaVOICE 100 the belief that understanding the critical factors that influence individual behavior and creating a dialogue that addresses those factors is the best way of building enduring relationships between customers and brands.

Unlike traditional agencies that are "siloed" or structured by discipline, MicroMass brings together under one roof the expertise and services for building sophisticated, multi-channel programs that span the full relationship marketing continuum.

Headquartered in Cary, N.C., with a second office in Morristown, N.J., MicroMass is one of the fastest growing agencies in its field. With experience in more than 30 therapeutic categories, the company has a roster of clients that includes GlaxoSmithKline, Johnson & Johnson, LabCorp, Merck & Co., Inc., Novartis, Shire and UCB Pharma.

For additional information on MicroMass, visit '/>"/>

SOURCE MicroMass Communications, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. North Carolina Marketing Firm MicroMass Named One of Top 60 Healthcare Agencies in U.S.
2. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
3. Rhode Island Governor Donald L. Carcieri and Dr. John C. Zolper, Vice President, Raytheon Company to Speak at IMAPS 2008
4. David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager
5. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
6. HistoRx Names Bill Sullivan Senior Vice President, Diagnostic Operations
7. The TPAA Names Mark Oelschlager President
8. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
9. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
10. Axendias President to Chair 3rd Annual MES for Life Sciences Congress
11. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4